Literature DB >> 26246004

IgG Subclass Specificity Discriminates Restricted IgM Rheumatoid Factor Responses From More Mature Anti-Citrullinated Protein Antibody-Associated or Isotype-Switched IgA Responses.

Willem J J Falkenburg1, Dirkjan van Schaardenburg2, Pleuni Ooijevaar-de Heer3, Gertjan Wolbink4, Theo Rispens3.   

Abstract

OBJECTIVE: To investigate the presence and patterns of specific IgG subclass recognition by IgM rheumatoid factor (IgM-RF) and IgA-RF with a newly developed enzyme-linked immunosorbent assay (ELISA), which can discriminate between polyspecific and restricted RF responses.
METHODS: Polyspecific and restricted RF responses were determined with our ELISA, which uses individually coated recombinant IgG subclasses instead of polyclonal IgG as target antibodies. Fine specificity was determined using target antibodies with single amino acid mutations in the Fc region.
RESULTS: In a screening panel of 93 sera that were previously found to be IgM-RF positive in a conventional RF assay, we were able to discriminate between sera with polyspecific IgM-RF responses (i.e., RF responses directed against all 4 IgG subclasses) and those with restricted IgM-RF responses, with low or absent relative reactivity against IgG2, IgG3, or IgG4. We found the largest variation for anti-IgG3 reactivity. Samples without detectable anti-IgG4 reactivity formed an independent group from the other restricted RF responses and the polyspecific RF responses. The specificity of these anti-IgG4-negative sera could be pinpointed to single amino acid differences between IgG1 and IgG4. Polyspecific RF responses more often showed signs of RF response maturation, with more isotype switching to IgA-RF, as compared to restricted RF responses. In a cohort of IgM-RF+ and/or anti-citrullinated protein antibody (ACPA)-positive arthralgia patients, we found restricted RF responses in 35% (49 of 140) of RF+/ACPA- patients, while RF+/ACPA+ patients, who have a much higher risk of developing rheumatoid arthritis, virtually always (123 of 128 [96%]) showed a polyspecific RF response.
CONCLUSION: IgG subclass-specific RF distinguishes between immature restricted RF responses and potentially more pathogenic, ACPA-associated polyspecific responses.
© 2015, American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26246004     DOI: 10.1002/art.39299

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  6 in total

Review 1.  Autoimmunity, inflammation, and dysbiosis mutually govern the transition from the preclinical to the clinical stage of rheumatoid arthritis.

Authors:  Alexander Kalinkovich; Gulzan Gabdulina; Gregory Livshits
Journal:  Immunol Res       Date:  2018-12       Impact factor: 2.829

Review 2.  How Rheumatoid Arthritis Can Result from Provocation of the Immune System by Microorganisms and Viruses.

Authors:  Marina I Arleevskaya; Olga A Kravtsova; Julie Lemerle; Yves Renaudineau; Anatoly P Tsibulkin
Journal:  Front Microbiol       Date:  2016-08-17       Impact factor: 5.640

3.  Rheumatoid Arthritis Patients With Circulating Extracellular Vesicles Positive for IgM Rheumatoid Factor Have Higher Disease Activity.

Authors:  Onno J Arntz; Bartijn C H Pieters; Rogier M Thurlings; Mark H Wenink; Peter L E M van Lent; Marije I Koenders; Frank H J van den Hoogen; Peter M van der Kraan; Fons A J van de Loo
Journal:  Front Immunol       Date:  2018-10-29       Impact factor: 7.561

4.  Rheumatoid Factor: A Novel Determiner in Cancer History.

Authors:  Alessio Ugolini; Marianna Nuti
Journal:  Cancers (Basel)       Date:  2021-02-03       Impact factor: 6.639

5.  Middle east pain syndrome is a pollution-induced new disease mimicking rheumatoid arthritis.

Authors:  Adel A Elbeialy; Abdlnby M Bauomi; Basma M Elnaggar; Hala M Elzomor
Journal:  Sci Rep       Date:  2021-11-15       Impact factor: 4.379

6.  Determination of Autoantibody Isotypes Increases the Sensitivity of Serodiagnostics in Rheumatoid Arthritis.

Authors:  Daniela Sieghart; Alexander Platzer; Paul Studenic; Farideh Alasti; Maresa Grundhuber; Sascha Swiniarski; Thomas Horn; Helmuth Haslacher; Stephan Blüml; Josef Smolen; Günter Steiner
Journal:  Front Immunol       Date:  2018-04-24       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.